Should I Buy AGEN? AGEN 2026 Analysis

Should You Buy Agenus Inc (AGEN) Today? Analysis, Price Targets, and 2026 Outlook.

Conclusion

Hold

Latest Price

2.940

1 Day change

6.14%

52 Week Range

7.340

Analysis Updated At

2026/02/04

Should I buy Analysis is updated weekly. For real time "Should I Buy" analysis, please sign up to get free answers.

Not a good buy right now for an impatient buyer: trend is still bearish (SMA_200 > SMA_20 > SMA_5) and momentum hasn’t flipped.
Nearest support (S1 ~2.861) is close; upside levels to clear are Pivot ~3.148 then R1 ~3.434—risk/reward isn’t compelling until price reclaims the pivot with improving momentum.
Options positioning is very call-heavy (bullish sentiment), but absolute option volume is tiny, so the signal is weaker than it looks.
Intellectia Proprietary Trading Signals
- AI Stock Picker: No signal on given stock today.
- SwingMax: No signal on given stock today.

Technical Analysis

Trend: Bearish structure with moving averages stacked down (SMA_200 > SMA_20 > SMA_5) → sellers still control the bigger picture.
Momentum: MACD histogram -0.0663 (below 0) but “negatively contracting” → downside momentum may be easing, not yet bullish.
RSI(6): ~31.1 (near oversold territory) → could bounce short-term, but not a confirmed reversal.
Key levels: Support S1 ~2.861 (then S2 ~2.684). Resistance Pivot ~3.148, then R1 ~3.434 and R2 ~3.611.
Pattern-based short-horizon odds: model indicates weakness over 1W (-4.22%) and 1M (-6.86%), which argues against chasing now.

Options Data

Bullish

Open Interest Put-Call Ratio

Bullish

Option Volume Put-Call Ratio

Sentiment: Extremely call-skewed (OI put/call 0.11; volume put/call 0.08) → bullish positioning.
Liquidity/strength of signal: Today’s options volume is only 26 contracts (24 calls / 2 puts) → skew is bullish but based on very small activity.
Volatility: IV30 ~127% vs HV ~63.7% → options are pricing large moves; premium is expensive.
IV context: IV percentile ~47 and IV rank ~21.8 → elevated but not at extremes versus its own history.
Flow intensity: volume vs 30D avg ~7.95x and open interest vs avg ~110x (from a low base) → “spike” metrics look strong, but confirm with sustained volume.

Technical Summary

Sell

Buy

Positive Catalysts

- Options market skew is strongly call-leaning (bullish sentiment).
- RSI near oversold can support a short-term bounce if buyers defend ~2.86 support.
- Q3 2025 revenue grew +20.4% YoY, showing top-line momentum.

Neutral/Negative Catalysts

- Clear bearish trend (MA stack) with price below key pivot (~3.148).
- Pattern-based projection points to weakness over the next week/month.
- No news catalysts in the past week to spark a reversal.
- Institutional/insider trend read is neutral (no supportive accumulation signal).
- No recent congress trading data available (no external “influential” confirmation).

Financial Performance

Latest quarter: 2025/Q3.
Revenue: $30.235M, +20.40% YoY (growth positive).
Net income: $63.86M, -196.12% YoY (meaningfully worse vs prior year; suggests elevated losses/charges vs prior period).
EPS: 1.94, -162.99% YoY (deterioration YoY).
Gross margin: 97.88%, down -1.55% YoY (still very high but slightly compressing).

Growth

Profitability

Efficiency

Analyst Ratings and Price Target Trends

No analyst rating trend or price target change data was provided, so there’s no confirmed recent Wall Street upgrade/downgrade signal to lean on.
Wall Street-style pros (based on available data): revenue growth remains strong; very high gross margin profile.
Wall Street-style cons (based on available data): profitability/EPS trend deteriorated sharply YoY; technical trend remains bearish, so fundamental optimism isn’t translating into price strength.

1 Analyst Rating

Wall Street analysts forecast AGEN stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for AGEN is 23 USD with a low forecast of 23 USD and a high forecast of 23 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

1 Buy

0 Hold

0 Sell

Moderate Buy

Current: 2.770

Low

Averages

High

Current: 2.770

Low

Averages

High

H.C. Wainwright

Neutral -> Buy

upgrade

$25

AI Analysis

2025-06-04

Reason

H.C. Wainwright

Price Target

$25

AI Analysis

2025-06-04

upgrade

Neutral -> Buy

Reason

H.C. Wainwright upgraded Agenus to Buy from Neutral with a $25 price target after the company entered into a strategic collaboration with Indian multinational pharmaceutical company Zydus Lifesciences. The definitive partnership is valued at up to $141M and is aimed at accelerating the clinical development of botensilimab and balstilimab while also securing scaled manufacturing both domestically and outside the U.S., the analyst tells investors in a research note. Th firm says that given Agenus' commitment to reducing its cash burn and the capital provided from this partnership, it now believes the company has sufficient funding to advance botensilimab and balstilimab through a Phase 3 trial initiating in the second half of 2025.

Baird

Neutral

maintain

$4 -> $6

2025-06-04

Reason

Baird

Price Target

$4 -> $6

2025-06-04

maintain

Neutral

Reason

Baird raised the firm's price target on Agenus to $6 from $4 and keeps a Neutral rating on the shares. The firm updatedits model following the receipt of ts $91M upfront payment from its strategic collaboration with Zydus.

Unlock Full Analyst Thesis， Get the complete breakdown of rating reason for AGEN

Unlock Now

AGEN Should I Buy

AGEN Should I Buy

Should You Buy Agenus Inc (AGEN) Today? Analysis, Price Targets, and 2026 Outlook.

Technical Analysis

Options Data

Technical Summary

Positive Catalysts

Neutral/Negative Catalysts

Financial Performance

Growth

Profitability

Efficiency

Analyst Ratings and Price Target Trends

People Also Watch